Publications

Peer-Reviewed Articles

57. Coughlin JM, Slania S, Du Y, Shinehouse LK, Brosnan MK, Azad BB, Holt DP, Fan H, Lesniak WG, Minn I, Rowe SP, Dannals RF, Horti AG, Pomper MG. First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3122-3128. doi: 10.1007/s00259-021-05231-4.

 

56. Du Y, Minn I, Foss C, Lesniak WG, Hu F, Dannals RF, Pomper MG, Horti AG. PET imaging of soluble

epoxide hydrolase in non-human primate brain with [18F]FNDP. EJNMMI Res. 2020 Jun 22;10(1):67. doi:

10.1186/s13550-020-00657-7.

 

55. Du Y, Coughlin JM, Brosnan MK, Chen A, Shinehouse LK, Abdallah R, Lodge MA, Mathews WB, Liu C, Wu Y, Minn I, Finley P, Hall AW, Lesniak WG, Dannals RF, Horti AG, Pomper MG. First-in-human

imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2. Eur J Nucl Med Mol

Imaging. 2023 Mar 6. doi: 10.1007/s00259-023-06170-y.

 

54. Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW, Dalaie P, Tulbah R, Yin Y,

VanDenBerg R, Werner RA, Pienta KJ, Gorin MA, Du Y, Pomper MG. Deep learning and radiomics

framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res. 2022 Dec

29;12(1):76. doi: 10.1186/s13550-022-00948-1.

 

53. Coughlin JM, Du Y, Lesniak WG, Harrington CK, Brosnan MK, O'Toole R, Zandi A, Sweeney SE,

Abdallah R, Wu Y, Holt DP, Hall AW, Dannals RF, Solnes L, Horti AG, Pomper MG. First-in-human use

of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor

1 receptor. EJNMMI Res. 2022 Sep 30;12(1):64. doi: 10.1186/s13550-022-00929-4.

 

52. Levinstein MR, Ventriglia EN, Gomez JL, Budinich RC, Marton J, Henriksen G, Holt DP, Dannals RF,

Pomper MG, Zarate CA Jr, Bonaventura J, Michaelides M. 6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-

Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo. Mol Imaging Biol. 2023

Apr;25(2):384-390. doi: 10.1007/s11307-022-01767-5.

 

51. Cheng B, Ahn HH, Nam H, Jiang Z, Gao FJ, Minn I, Pomper MG. A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects. Pharmaceutics. 2022 Feb 7;14(2):373. doi: 10.3390/pharmaceutics14020373.

 

50. Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer

Patients. J Nucl Med. 2022 Apr;63(4):536-542. doi: 10.2967/jnumed.121.262045.

 

49. Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Narrative review

of generative adversarial networks in medical and molecular imaging. Ann Transl Med. 2021 May;9(9):821. doi: 10.21037/atm-20-6325.

 

48. Liu HW, Hu Y, Ren Y, Nam H, Santos JL, Ng S, Gong L, Brummet M, Carrington CA, Ullman CG, Pomper MG, Minn I, Mao HQ. Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery. ACS Appl Mater Interfaces. 2021 Jul 7;13(26):30326-30336. doi: 10.1021/acsami.1c05750.

 

47. Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, Gorin MA, Wang NY,

Rowe SP. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-

labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-

Resistant Prostate Cancer. Eur Urol. 2021 Jul;80(1):82-94. doi: 10.1016/j.eururo.2021.03.004.

 

46. Vaidyanathan G, Mease RC, Minn I, Choi J, Chen Y, Shallal H, Kang CM, McDougald D, Kumar V,

Pomper MG, Zalutsky MR. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostatespecific

membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021

Mar-Apr;94-95:67-80. doi: 10.1016/j.nucmedbio.2021.01.002.

 

45. Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM,

Pomper MG, Banerjee SR. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy

enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.

Nanotheranostics. 2021 Jan 19;5(2):182-196. doi: 10.7150/ntno.52361.

 

44. Hu F, Morris PJ, Bonaventura J, Fan H, Mathews WB, Holt DP, Lam S, Boehm M, Dannals RF, Pomper MG, Michaelides M, Horti AG. Eur J Med Chem. 2021 Mar 5;213:113047. doi:

10.1016/j.ejmech.2020.113047.

 

43. Rowe, S. P., Pomper, M. G. (2021) Molecular imaging in oncology: current impact and future directions.

CA Cancer J Clin caac.21713

 

42. Hapuarachchige, S. Si, G., Huang, C. T., Lesniak, W. G., Mease, R., Guo, X., Gabrielson, K., Artemov,

D. (2021) Dual-modality PET-SPECT image-guided pretargeting delivery in HER2(+) breast cancer

models. Biomacromolecules 22, 4606-4617

 

41. Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC,

Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S.

Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.

Proc Natl Acad Sci U S A. 2021 Sep14;118(37):e2107982118. PMID: 34508005

 

40. Leung K. H., Rowe, S. P., Pomper, M. G., Du, Y. A three-stage, deep learning, ensemble approach for

prognosis in patients with Parkinson’s disease. (2021) EJNMMI Res 11, 52

 

39. Mease, R. C., Kang, C. M., Kumar, V., Banerjee, S. R., Minn, I., Brummet, M., Gabrielson, K. L., Feng,

Y., Park, A., Kiess, A. P., Sgouros, G., Vaidyanathan, G., Zalutsky, M. R., Pomper, M. G. (2021) An

improved 211At-labeled agent for PSMA-targeted alpha therapy. J Nucl Med jnumed.121.262098

 

38. Khatri W., Chung H. W., Werner, R. A., Leal, J. P., Pienta, K. J., Lodge, M. A., Gorin, M. A., Pomper, M.G., Rowe, S. P. (2021) Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A

lesions on PSMA-targeted PET imaging of men with prostate cancer. Diagnostics 11, 665

 

37. Ordonez, A. A., Wintaco, L. M., Mota, F., Restrepo, A. F., Ruiz-Bedoya, C. A., Reyes, C. F., Uribe, L. G.,

Abhishek, S., D’Alessio, F. R., Holt, D. P., Dannals, R. F., Rowe, S. P., Castillo, V. R., Pomper, M. G.,

Granados, U., Jain, S. K. (2021) Imaging Enterobacterales infections in patients using pathogen-specific

positron emission tomography. Sci Transl Med 13, scitranslmed.abe9805

 

36. Sadaghiani, M. S., Sheikhbahaei, S., Werner, R. A., Pienta, K. J., Pomper, M. G., Solnes, L. B., Gorin,

M. A., Rowe, S. P. (2021) A systematic review and meta-analysis of the effectiveness and toxicities of

lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic

castration-resistant prostate cancer. Eur Urol 80, 82-94

 

35. Slania, S. L., Das, D., Lisok, A., Du, Y., Jiang, Z., Mease, R. C., Rowe, S. P., Nimmagadda, S., Yang, X.,

Pomper, M. G. (2021) Imaging of fibroblast activation protein in cancer xenografts using novel (4-

quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules. J Med Chem 64, 4059-4070

 

34. Vaidyanathan, G., Kang, C. M., McDougald, D., Minn, I., Brummet, M., Pomper, M. G., and Zalutsky, M.

R. (2018) Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled

prostate-specific membrane antigen inhibitors. Nucl Med Biol 62-63, 18-30

 

33. De Silva, R., Gorin, M. A., Mease, R. C., Minn, I., Lisok, A., Plyku, D., Nimmagadda, S., Allaf, M. E.,

Yang, X., Sgouros, G., Rowe, S. P., Pomper, M.G. (2021) Process validation, cGMP production,

dosimetry, and toxicity studies of the CAIX imaging agent [111In]In-XYIMSR-01 for phase I regulatory

approval. J Labelled Comp Radiopharm 64, 243-250

 

32. Ngen, E. J., Benham Azad, B., Boinapally, S., Lisok, A., Brummet, M., Jacob, D., Pomper, M. G., and

Banerjee, S. R. (2019) MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a

PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. Mol Pharm 16, 2060-2068

 

31. Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A., Ellis, R.

J., Richie, C. T., Harvey, B. K., Dannals, R. F., Pomper, M. G., Bonci, A., and Michaelides, M. (2017)

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science 357,

503-507

 

30. Ray, S., Lisok, A., Minn, I, Josefsson, A., Kumar, V., Brummet, M., Boinapally, S., Brayton, C., Mease,

R. C., Sgouros, G., Hobbs, R. F., Pomper, M. G. (2021) Preclinical evaluation of 213Bi-/225Ac-labeled low molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med 62 980-988

 

29. Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities

and Challenges. Cancers (Basel). 2020 Oct 29;12(11):3173. PMID: 33137949

 

28. Santhanam, P. Russell, J., Rooper, L. M., Ladenson, P. W., Pomper, M. G., Rowe, S. P. (2020) The

prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor

neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Med Oncol

37, 98

 

27. Huang, C. T., Guo, X., Barinka, C., Lupold, S. E., Pomper, M. G., Gabrielson, K., Raman, V., Artemov,

D., and Hapuarachchige, S. (2020) Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane

Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Mol Pharm 17, 3392-

3402

 

26. Plavén-Sigray, P., Matheson, G. J., Coughlin, J. M., Hafizi, S., Laurikainen, H., Ottoy, J., De Picker, L.,

Rusjan, P., Hietala, J., Howes, O. D., Mizrahi, R., Morrens, M., Pomper, M. G., and Cervenka, S. (2021)

Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of

Patient-Control Differences. Biol Psychiatry 89, e5-e8

 

25. Leung, K. H., Marashdeh, W., Wray, R., Ashrafinia, S., Pomper, M. G., Rahmim, A., and Jha, A. K. (2020)

A physics-guided modular deep-learning based automated framework for tumor segmentation in PET.

Phys Med Biol 65, 245032

 

24. Werner, R. A., Derlin, T. Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S., Drzezga, A.,

Kimura, H., Buck, A. K., Derlin, T., Bengel, F. M., Pomper, M. G., Gorin, M. A., Rowe, S. P. (2020) 18F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer

molecular imaging. Theranostics 10, 1-16

 

23. Hapuarachchige, S., Huang, C. T., Donnelly, M. C., Barinka, C., Lupold, S. E., Pomper, M. G., and

Artemov, D. (2020) Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive

Prostate Cancer. Mol Pharm 17, 98-108

 

22. Hu, Y., He, Z., Hao, Y., Gong, L., Pang, M., Howard, G. P., Ahn, H. H., Brummet, M., Chen, K., Liu, H.

W., Ke, X., Zhu, J., Anderson, C. F., Cui, H., Ullman, C. G., Carrington, C. A., Pomper, M. G., Seo, J. H.,

Mittal, R., Minn, I., and Mao, H. Q. (2019) Kinetic Control in Assembly of Plasmid DNA/Polycation

Complex Nanoparticles. ACS Nano 13, 10161-10178

 

21. Banerjee, S. R., Kumar, V., Lisok, A., Chen, J., Minn, I., Brummet, M., Boinapally, S., Cole, M., Ngen, E.,

Wharram, B., Brayton, C., Hobbs, R. F., and Pomper, M. G. (2019) (177)Lu-labeled low-molecular-weight

agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging 46, 2545-2557

 

20. Peters, M. E., Rahman, S., Coughlin, J. M., Pomper, M. G., and Sair, H. I. (2020) Characterizing the Link

Between Glial Activation and Changed Functional Connectivity in National Football League Players Using

Multimodal Neuroimaging. J Neuropsychiatry Clin Neurosci 32, 191-195

 

19. Rowe, S. P., Solnes, L. B., Yin, Y., Kitchen, G., Lodge, M. A., Karakatsanis, N. A., Rahmim, A., Pomper,

M. G., and Leal, J. P. (2019) Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting

Radiomic Parameters from PET Data. J Digit Imaging 32, 1071-1080

 

18. Paller, C. J., Piana, D., Eshleman, J. R., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S. P.,

Pomper, M. G., Antonarakis, E. S., Luo, J., and Eisenberger, M. A. (2019) A pilot study of prostatespecific

membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate 79, 1597-1603

 

17. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P.

(2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic

Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8

 

16. Minn, I., Huss, D. J., Ahn, H. H., Chinn, T. M., Park, A., Jones, J., Brummet, M., Rowe, S. P., Sysa-Shah,

P., Du, Y., Levitsky, H. I., and Pomper, M. G. (2019) Imaging CAR T cell therapy with PSMA-targeted

positron emission tomography. Sci Adv 5, eaaw5096

 

15. Lesniak, W. G., Mease, R. C., Chatterjee, S., Kumar, D., Lisok, A., Wharram, B., Kalagadda, V. R.,

Emens, L. A., Pomper, M. G., and Nimmagadda, S. (2019) Development of [(18)F]FPy-WL12 as a PDL1

Specific PET Imaging Peptide. Mol Imaging 18, 1536012119852189

 

14. Song, X., Walczak, P., He, X., Yang, X., Pearl, M., Bulte, J. W. M., Pomper, M. G., McMahon, M. T., and

Janowski, M. (2016) Salicylic acid analogues as chemical exchange saturation transfer MRI contrast

agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial

infusion. J Cereb Blood Flow Metab 36, 1186-1194

 

13. Werner, R. A., Bundschuh, R. A., Bundschuh, L., Lapa, C., Yin, Y., Javadi, M. S., Buck, A. K., Higuchi,

T., Pienta, K. J., Pomper, M. G., Lodge, M. A., Gorin, M. A., and Rowe, S. P. (2020) Semiquantitative

Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Impact of Tumor Burden on Normal

Organ Uptake. Mol Imaging Biol 22, 190-197

 

12. Sahakyan, K., Li, X., Lodge, M. A., Werner, R. A., Bundschuh, R. A., Bundschuh, L., Kulkarni, H. R.,

Schuchardt, C., Baum, R. P., Pienta, K. J., Pomper, M. G., Ross, A. E., Gorin, M. A., and Rowe, S. P.

(2020) Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Intrapatient

and Interpatient Variability of Normal Organ Uptake. Mol Imaging Biol 22, 181-189

 

11. Coughlin, J. M., Horti, A. G., and Pomper, M. G. (2019) Opportunities in precision psychiatry using PET

neuroimaging in psychosis. Neurobiol Dis 131, 104428

 

10. Gomez, E., Tran, P. T., Pienta, K. J., Pomper, M. G., Gorin, M. A., and Rowe, S. P. (2019) Hereditary

Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted

18F-DCFPyL PET/CT. Clin Nucl Med 44, e313-e314

 

9. Reyes, D. K., Demehri, S., Werner, R. A., Pomper, M. G., Gorin, M. A., Rowe, S. P., and Pienta, K. J.

(2019) PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical

decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 23, 72-74

 

8. Horti, A. G., Naik, R., Foss, C. A., Minn, I., Misheneva, V., Du, Y., Wang, Y., Mathews, W. B., Wu, Y.,

Hall, A., LaCourse, C., Ahn, H. H., Nam, H., Lesniak, W. G., Valentine, H., Pletnikova, O., Troncoso, J.

C., Smith, M. D., Calabresi, P. A., Savonenko, A. V., Dannals, R. F., Pletnikov, M. V., and Pomper, M.

G. (2019) PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A 116, 1686-1691

 

7. Coughlin, J. M., Yang, T., Rebman, A. W., Bechtold, K. T., Du, Y., Mathews, W. B., Lesniak, W. G., Mihm,

E. A., Frey, S. M., Marshall, E. S., Rosenthal, H. B., Reekie, T. A., Kassiou, M., Dannals, R. F., Soloski, M. J., Aucott, J. N., and Pomper, M. G. (2018) Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [(11)C]DPA-713 PET. J Neuroinflammation 15, 346

 

6. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P.,

Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu,

J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of

PD-L1 therapeutics. J Clin Invest 129, 616-630

 

5. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P.

(2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic

Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8

 

4. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P.,

Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu,

J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of

PD-L1 therapeutics. J Clin Invest 129, 616-630

 

3. Foss, C. A., Kulik, L., Ordonez, A. A., Jain, S. K., Michael Holers, V., Thurman, J. M., and Pomper, M. G.

(2019) SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [(125)I]anti-C3d mAb. Mol

Imaging Biol 21, 473-481

 

2. Foss, C. A., Plyku, D., Ordonez, A. A., Sanchez-Bautista, J., Rosenthal, H. B., Minn, I., Lodge, M. A.,

Pomper, M. G., Sgouros, G., and Jain, S. K. (2018) Biodistribution and Radiation Dosimetry of (124)IDPA-

713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med 59, 1751-1756

 

1. Zukotynski, K. A., Valliant, J., Benard, F., Rowe, S. P., Kim, C. K., Pomper, M. G., and Cho, S. Y. (2018)

Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in

Castration-Resistant Prostate Cancer: First Observations. Clin Nucl Med 43, 213-216

Book Chapters

5. Rowe, S. P., Werner, R. A., Garg, T., Gafita, A., Voter, A. F., Sadaghiani, M. S., Markowski, M. C., Paller,

C. J., Zalutsky, M. R., Solnes, L. B., Pomper, M. G. Small molecule vectors for endoradiotherapy. In:

Lewis, J. S., Bodei, L., Zeglis, B. M., eds. Endoradiotherapy. New York, NY: Springer, in press

​

4. Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer

J Clin. 2022 Jul;72(4):333-352. doi: 10.3322/caac.21713.

​

​3. Solnes, L. B., Jacobs, A. H., Coughlin, J. M., Du, Y., Goel, R., Hammoud, D. A., Pomper, M. G. (2020)

Central Nervous System Molecular Imaging. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging

Principles and Practice. Shelton, CT: People’s Medical Publishing House, in press

​

2. Rowe, S. P., Sadaghiani, M. S., Werner, R. A., Higuchi, T., Derlin, T., Solnes, L. B., Pomper, M. G. (2020)

Prostate Cancer Theranostics. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging Principles and

Practice. Shelton, CT: People’s Medical Publishing House, in press

​

1. Nimmagadda, S., Shelake, S., Pomper, M. G. (2019) Preclinical experimentation in oncology. In: Lewis,

J. S., Windhorst, A. D., Zeglis, B. M., eds. Radiopharmaceutical Chemistry. New York: Springer

​